New medication, TTYD: According to Gilead (maker of Solvadi), in their POSITRON trial, 61% of all pts with Type 3 HepC had a sustained virologic response (SVR) (lower Hep C virus blood counts) at 24 wks. See the package insert (PI) approved by the FDA: https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf. In the trial, those w/o cirrhosis were 68% likely to have SVR. TTYD about this.
Answered 9/24/2014
3.7k views
A doctor has provided 1 answer
3 doctors weighed in across 2 answers
6 doctors weighed in across 3 answers
A doctor has provided 1 answer
A doctor has provided 1 answer
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question